Larijani Mani, Frieder Darina, Sonbuchner Timothy M, Bransteitter Ronda, Goodman Myron F, Bouhassira Eric E, Scharff Matthew D, Martin Alberto
Department of Immunology, University of Toronto, Medical Sciences Bldg. 5265, Toronto, Canada, M5S 1A8.
Mol Immunol. 2005 Mar;42(5):599-604. doi: 10.1016/j.molimm.2004.09.007.
Somatic hypermutation (SHM), class switch recombination (CSR), and gene conversion of immunoglobulin genes require activation-induced cytidine deaminase (AID). AID initiates these events by deaminating cytidines within antibody variable and switch regions. The mechanism that restricts mutation to antibody genes is not known. Although genes other than antibody genes have been found to mutate, not all highly transcribed genes mutate. Thus, somatic hypermutation does not target all genes and suggests a mechanism that either recruits AID to genes for mutation, and/or one that protects genes from promiscuous AID activity. Recent evidence suggests that AID deaminates methyl cytidines inefficiently. Methylation of cytidines could thus represent a means to protect the genome from potentially harmful AID activity that occurs outside of the immunoglobulin loci. To test this premise, we examined whether AID could deaminate methylated-CpG motifs in different sequence contexts. In agreement with a report that suggests that AID has processive-like properties in vitro, we found that AID could completely deaminate single-stranded DNA tracks in plasmid substrates that were greater than 300 nucleotides in length. In addition, methylated-CpG motifs, but not their unmethylated counterparts, were protected from AID-mediated deamination. However, methylation did not protect cytidines that neighbored CpG motifs indicating that methylation per se does not provide a more global safeguard against AID-mediated activity. These data also suggest that AID, and possibly other related cytidine deaminases, might represent a more rapid alternative to bisulfite sequencing for identifying methylated-CpG motifs.
体细胞高频突变(SHM)、类别转换重组(CSR)以及免疫球蛋白基因的基因转换都需要激活诱导的胞嘧啶脱氨酶(AID)。AID通过使抗体可变区和转换区内的胞嘧啶脱氨来启动这些事件。限制抗体基因突变的机制尚不清楚。尽管已发现除抗体基因外的其他基因也会发生突变,但并非所有高转录基因都会突变。因此,体细胞高频突变并非针对所有基因,这表明存在一种机制,要么将AID招募到基因上进行突变,和/或一种保护基因免受AID随意作用的机制。最近的证据表明,AID对甲基化胞嘧啶的脱氨效率较低。因此,胞嘧啶的甲基化可能是一种保护基因组免受免疫球蛋白基因座外潜在有害AID活性影响的手段。为了验证这一前提,我们研究了AID是否能在不同序列背景下使甲基化的CpG基序脱氨。与一份表明AID在体外具有类似持续性特性的报告一致,我们发现AID能够完全使长度超过300个核苷酸的质粒底物中的单链DNA片段脱氨。此外,甲基化CpG基序而非未甲基化的对应基序能免受AID介导的脱氨作用。然而,甲基化并不能保护与CpG基序相邻的胞嘧啶,这表明甲基化本身并不能提供更全面地抵御AID介导活性的保护。这些数据还表明,AID以及可能的其他相关胞嘧啶脱氨酶,可能是一种比亚硫酸氢盐测序更快的识别甲基化CpG基序的替代方法。